Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, Matthew D Ducar, Yuxiang Tan, Linfeng Chen, Margaretha G M Roemer, Jing Ouyang, Amanda L Christie, Liye Zhang, Daniel Gusenleitner, Ryan P Abo, Pedro Farinha, Frederike von Bonin, Aaron R Thorner, Heather H Sun, Randy D Gascoyne, Geraldine S Pinkus, Paul van Hummelen, Gerald G Wulf, Jon C Aster, David M Weinstock, Stefano Monti, Scott J Rodig, Yuzhuo Wang, Margaret A Shipp
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defined by transcriptional classifications, specific signaling and survival pathways, and multiple low-frequency genetic alterations. Preclinical model systems that capture the genetic and functional heterogeneity of DLBCL are urgently needed. Here, we generated and characterized a panel of large B-cell lymphoma (LBCL) patient-derived xenograft (PDX) models, including 8 that reflect the immunophenotypic, transcriptional, genetic, and functional heterogeneity of primary DLBCL and 1 that is a plasmablastic lymphoma...
May 5, 2016: Blood